Platelet indexes in relation to target organ damage in high-risk hypertensive patients - A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

被引:150
作者
Nadar, SK [1 ]
Blann, AD [1 ]
Kamath, S [1 ]
Beevers, DG [1 ]
Lip, GYH [1 ]
机构
[1] Univ Birmingham, City Hosp, Dept Med, NHS Trust,Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England
关键词
D O I
10.1016/j.jacc.2004.03.067
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES We sought to investigate the relationship between target organ damage (TOD) in hypertension and a prothrombotic/hypercoagulable state, using a new technique of "platelet lysis" to quantify the amount of P-selectin per platelet (pP-sel), and to correlate it with other platelet markers (e.g., mass, volume and granularity, soluble P-selectin [sP-sel], and beta-thromboglobulin [beta-TG]). BACKGROUND The increased risk of TOD in hypertension may be related to a prothrombotic/hypercoagulable state, with abnormalities in platelets, such as increased expression of P-selectin. METHODS We studied 199 patients (mean age 68 years, 75% men) with hypertension. Of these, 125 had TOD (e.g., stroke, previous myocardial infarction, angina, left ventricular hypertrophy). Values obtained were compared with those from 59 healthy normotensive control subjects (mean age 68 years, 58% men). RESULTS Hypertensive patients had a higher mean platelet volume, mass, pP-sel, sP-sel, and beta-TG and lower platelet granularity (all p < 0.01), but a similar platelet count, as compared with controls. Within the hypertensive group, those with evidence of TOD had significantly larger platelets with greater mass but had lower granularity, sP-sel, and pP-sel levels than those without TOD, possibly reflecting increased aspirin use. On multivariate analysis, aspirin use was a determinant of pP-sel (p = 0.03) and sP-sel (p = 0.01), but the use of other drugs or other co-morbidity (e.g., diabetes, smoking) did not influence either P-selectin value. CONCLUSIONS Patients with hypertension have evidence of changes in platelet physiology, as reflected by a higher level of pP-sel. Patients with TOD also had larger platelets, with greater mass, and the use of aspirin lowered pP-sel and sP-sel levels. These changes may have implications for the pathophysiology of cardiovascular and cerebrovascular disease in hypertension. (C) 2004 by the American College of Cardiology Foundation.
引用
收藏
页码:415 / 422
页数:8
相关论文
共 51 条
[1]  
Altman DG, 1990, PRACTICAL STAT MED R
[2]   Pro-coagulant state resulting from high levels of soluble P-selecain in blood [J].
André, P ;
Hartwell, D ;
Hrachovinová, I ;
Saffaripour, S ;
Wagner, DD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (25) :13835-13840
[3]  
ARMANI KL, 1995, J LAB CLIN MED, V126, P603
[4]  
Barradas M A, 1992, In Vivo, V6, P629
[5]  
BATH PMW, 1994, J HUM HYPERTENS, V8, P457
[6]   Evidence of platelet activation in hypertension [J].
Blann, AD ;
Lip, GYH ;
Islim, IF ;
Beevers, DG .
JOURNAL OF HUMAN HYPERTENSION, 1997, 11 (09) :607-609
[7]   Pharmacological modulation of platelet function in hypertension [J].
Blann, AD ;
Nadar, S ;
Lip, GYH .
HYPERTENSION, 2003, 42 (01) :1-7
[8]  
Blann AD, 2001, THROMB HAEMOSTASIS, V86, P777
[9]  
Blann AD, 1999, CIRCULATION, V100, pE86
[10]  
Blann AD, 1997, THROMB HAEMOSTASIS, V77, P1077